Postoperative chemotherapy with Eribulin following potentially curative surgery in patients with localized liposarcoma – a retrospective single center experience

Abstract Introduction: Soft tissue sarcomas are rare and heterogenous malignancies with high recurrence rates following resection and a poor prognosis in advanced stages. Eribulin is used in metastatic soft tissue sarcoma patients, who have failed first line chemotherapy and has been approved in patients with pretreated advanced liposarcoma (LPS) in the United States and Europe due to data from a phase III trial. In addition, no data are available for eribulin as postoperative treatment after potentially curative surgery. We have thus retrospectively evaluated efficacy and tolerability of adjuvant eribulin in LPS patients not suitable for intensive chemotherapy in the routine clinical setting. Methods In this retrospective single center analysis, efficacy and safety of eribulin were retrospectively evaluated in 5 high risk LPS patients. Results Eribulin as postoperative treatment following surgical resection was administered to 5 patients with LPS. Median progression free survival (PFS) and overall survival (OS) were 12.3 months (95% CI 5.6–18.9 months) and 44.3 months (3.8–84.8 95% CI), respectively. Toxicity was generally manageable, and grade 3 + 4 events were rare. Conclusions Postoperative eribulin may be feasible in selected high risk LPS patients, who are not candidates for intensive chemotherapy regimens. Further prospective trials, however, are needed.